BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025
• 2026

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September

Day

• 1
• 2
• 3
• 4
• 6
• 7
• 8
• 9
• 10
• 11
• 13
• 14
• 15
• 16
• 17
• 18
• 20
• 21
• 22
• 23
• 24

• Press Releases

  Merck’s Remigromig, a Tri-specific Agonist of the Wingless-related Integration Site (Wnt) Pathway, Met Primary Endpoint in the Pivotal Phase 2b/3 BRUNELLO Study of Adults with Diabetic Macular Edema

  September 24, 2026

   · 

  7 min read
• Press Releases

  Coave Therapeutics to Present New Data on Wet AMD Gene Therapy Program at 26th Euretina Congress as it Advances towards the Clinic

  September 24, 2026

   · 

  2 min read
• Press Releases

  Medicenna Announces Oral Presentation of New Bizaxofusp Results in Recurrent Glioblastoma at the 2026 Society for Neuro-Oncology Annual Meeting

  September 24, 2026

   · 

  4 min read
• Press Releases

  Atavistik Bio Announces Strategic Research Collaboration with Roche to Discover and Develop Novel Allosteric Therapeutics

  September 24, 2026

   · 

  3 min read
• Press Releases

  Satellos Announces FDA Clearance of IND Application for Forazapadin in Facioscapulohumeral Muscular Dystrophy (FSHD) and a Partnership with FSHD Canada Foundation Providing Non-Dilutive Financing to Support Clinical Development

  September 24, 2026

   · 

  11 min read
• Press Releases

  Cullinan Therapeutics Highlights Fourth Quarter 2026 Milestones Across Immunology and Oncology T Cell Engager Portfolio

  September 24, 2026

   · 

  5 min read
• Press Releases

  Vistagen Reports Positive Findings Supporting Fasedienol’s Potential in Very Severe Social Anxiety Disorder

  September 24, 2026

   · 

  5 min read
• Press Releases

  Ligand and AvenCell Therapeutics Enter Financing Agreement to Advance Pipeline of Next-Generation CAR-T Therapies for Up to $47 Million

  September 24, 2026

   · 

  6 min read
• Press Releases

  PridCor Therapeutics Advances Phase 2 SHIELD Study of a Combination Antiviral Regimen for Long COVID Toward Enrollment

  September 24, 2026

   · 

  7 min read
• Press Releases

  Mesoblast Receives FDA Approval for New Potency Assay to Release Commercial Ryoncil Product

  September 24, 2026

   · 

  6 min read